COVID-19 vaccine induced interstitial lung disease

Ayumi Yoshifuji, Kota Ishioka, Yuya Masuzawa, Shuntaro Suda, Saori Murata, Yoshifumi Uwamino, Motoko Fujino, Hiromi Miyahara, Naoki Hasegawa, Munekazu Ryuzaki, Haruhiko Hoshino, Kazuhiko Sekine

研究成果: Article査読

抄録

A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes.

本文言語English
ページ(範囲)95-98
ページ数4
ジャーナルJournal of Infection and Chemotherapy
28
1
DOI
出版ステータスAccepted/In press - 2021

ASJC Scopus subject areas

  • 微生物学(医療)
  • 感染症
  • 薬理学(医学)

フィンガープリント

「COVID-19 vaccine induced interstitial lung disease」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル